China’s integrated biopharma ecosystem is challenging long-standing assumptions about the speed, cost, and structure of global drug development. In this interview, Caidya Executive Chairman Lingshi Tan examines how regulatory reform, globally trained talent, advanced clinical infrastructure, and closer collaboration across the development ecosystem have helped position China as a major source of biopharmaceutical innovation. He also discusses the growing importance of cross-border development strategies and why sponsors need globally integrated partners with meaningful local expertise.
The conversation offers a practical perspective on how combining China’s speed and operational integration with Western regulatory experience could support more efficient development and broader patient access worldwide.
Back to Resource Center